Evaluating the Effect of Benralizumab in Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI (AERFLO)
A Mechanistic Pilot Open-label Study to Evaluate the Effect of Benralizumab on Airway Function and Inflammation in Patients With Severe, Poorly-controlled Eosinophilic Asthma Using Inhaled Hyperpolarized 129-Xenon MRI
Sponsor: AstraZeneca
Listed as NCT03733535, this NA trial focuses on Asthma; Eosinophilic and remains ongoing. Sponsored by AstraZeneca, it has been updated 11 times since 2022, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting NA
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting NA
-
Jun 2023 — Jul 2024 [monthly]
Active Not Recruiting NA
-
Nov 2022 — Jun 2023 [monthly]
Active Not Recruiting NA
▶ Show 6 earlier versions
-
Jan 2021 — Nov 2022 [monthly]
Active Not Recruiting NA
-
Oct 2020 — Jan 2021 [monthly]
Active Not Recruiting NA
-
Mar 2020 — Oct 2020 [monthly]
Active Not Recruiting NA
Status: Recruiting → Active Not Recruiting
-
Jan 2020 — Mar 2020 [monthly]
Recruiting NA
-
May 2019 — Jan 2020 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Dec 2018 — May 2019 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
- Dr. Grace Parraga
For direct contact, visit the study record on ClinicalTrials.gov .